In vitro education of human natural killer cells by KIR3DL1.


Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
12 2019
Historique:
received: 20 05 2019
revised: 01 11 2019
accepted: 04 11 2019
entrez: 15 11 2019
pubmed: 15 11 2019
medline: 23 7 2020
Statut: epublish

Résumé

During development, NK cells are "educated" to respond aggressively to cells with low surface expression of HLA class I, a hallmark of malignant and infected cells. The mechanism of education involves interactions between inhibitory killer immunoglobulin-like receptors (KIRs) and specific HLA epitopes, but the details of this process are unknown. Because of the genetic diversity of HLA class I genes, most people have NK cells that are incompletely educated, representing an untapped source of human immunity. We demonstrate how mature peripheral KIR3DL1

Identifiants

pubmed: 31723004
pii: 2/6/e201900434
doi: 10.26508/lsa.201900434
pmc: PMC6856763
pii:
doi:

Substances chimiques

Epitopes 0
HLA-B Antigens 0
KIR3DL1 protein, human 0
Ligands 0
Receptors, KIR 0
Receptors, KIR3DL1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI017892
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI136952
Pays : United States

Informations de copyright

© 2019 Pugh et al.

Références

Front Immunol. 2018 Sep 10;9:2041
pubmed: 30250471
Blood. 2011 Jan 6;117(1):98-107
pubmed: 20935255
J Exp Med. 2010 Sep 27;207(10):2065-72
pubmed: 20819928
J Exp Med. 1976 Apr 1;143(4):772-80
pubmed: 1082915
BMC Med Genomics. 2018 Mar 27;11(1):36
pubmed: 29587858
J Immunol. 1987 Mar 15;138(6):1657-9
pubmed: 3819393
J Exp Med. 2010 Sep 27;207(10):2073-9
pubmed: 20819924
Front Immunol. 2017 Jul 18;8:832
pubmed: 28769934
J Immunol. 2005 Oct 15;175(8):5222-9
pubmed: 16210627
Nat Rev Immunol. 2006 Jul;6(7):520-31
pubmed: 16799471
Front Immunol. 2015 Apr 29;6:202
pubmed: 25972872
J Exp Med. 2006 Mar 20;203(3):633-45
pubmed: 16533882
J Exp Med. 2010 Nov 22;207(12):2663-73
pubmed: 21078887
J Immunol. 2018 Feb 1;200(3):1146-1158
pubmed: 29263215
Nat Commun. 2019 Jan 31;10(1):514
pubmed: 30705279
Immunol Rev. 1998 Jun;163:217-36
pubmed: 9700513
Immunol Today. 1997 Jun;18(6):292-9
pubmed: 9190116
Autoimmun Rev. 2019 Mar;18(3):306-311
pubmed: 30639645
J Immunol. 1979 Jul;123(1):342-9
pubmed: 87477
Science. 1995 Apr 21;268(5209):405-8
pubmed: 7716543
Gene. 1989 Apr 15;77(1):51-9
pubmed: 2744487
Semin Cancer Biol. 2012 Aug;22(4):350-8
pubmed: 22465194
Immunol Rev. 2015 Sep;267(1):259-82
pubmed: 26284483
J Exp Med. 1996 Dec 1;184(6):2243-50
pubmed: 8976179
PLoS Pathog. 2013;9(5):e1003383
pubmed: 23717207
J Med Virol. 1989 Aug;28(4):223-30
pubmed: 2550582
Nature. 1986 Feb 20-26;319(6055):675-8
pubmed: 3951539
Biol Blood Marrow Transplant. 2017 Mar;23(3):398-404
pubmed: 27894857
Hum Immunol. 2016 Mar;77(3):233-237
pubmed: 26826444
Curr Opin Immunol. 2003 Jun;15(3):308-14
pubmed: 12787756
Tissue Antigens. 2008 Nov;72(5):415-24
pubmed: 18946929
Am J Hum Genet. 2016 Aug 4;99(2):375-91
pubmed: 27486779
Blood. 2009 Jul 2;114(1):95-104
pubmed: 19304956
Immunity. 2006 Aug;25(2):331-42
pubmed: 16901727
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3053-8
pubmed: 18287063
J Immunol. 1997 Feb 15;158(4):1628-33
pubmed: 9029098
J Immunol. 2008 Nov 1;181(9):6293-300
pubmed: 18941220
PLoS One. 2012;7(10):e47664
pubmed: 23112830
J Biol Chem. 2019 Mar 22;294(12):4644-4655
pubmed: 30696773
Clin Exp Immunol. 1974 Jan;16(1):99-109
pubmed: 4143189
J Immunol. 2008 Mar 15;180(6):3969-79
pubmed: 18322206
J Immunol. 2016 Apr 15;196(8):3398-410
pubmed: 26962229
Hum Genet. 1986 Aug;73(4):320-6
pubmed: 3017841
J Exp Med. 2002 Dec 2;196(11):1403-14
pubmed: 12461076
Blood. 2010 Feb 11;115(6):1166-74
pubmed: 19903900
PLoS Genet. 2017 Jun 26;13(6):e1006862
pubmed: 28650991
Hum Immunol. 2018 Dec;79(12):825-833
pubmed: 30321631
Elife. 2017 Sep 06;6:
pubmed: 28875936
Nat Rev Immunol. 2013 Feb;13(2):133-44
pubmed: 23334245
Front Immunol. 2014 Sep 15;5:439
pubmed: 25309538
J Immunol. 2001 May 1;166(9):5695-703
pubmed: 11313411
Eur J Immunol. 2009 Sep;39(9):2548-55
pubmed: 19701893
J Exp Med. 2001 Nov 19;194(10):1507-17
pubmed: 11714757
Elife. 2018 Jul 10;7:
pubmed: 29989547

Auteurs

Jason Pugh (J)

Departments of Structural Biology and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA.

Neda Nemat-Gorgani (N)

Departments of Structural Biology and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA.

Zakia Djaoud (Z)

Departments of Structural Biology and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA.

Lisbeth A Guethlein (LA)

Departments of Structural Biology and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA.

Paul J Norman (PJ)

Division of Biomedical Informatics and Personalized Medicine, Department of Immunology, School of Medicine, University of Colorado Denver, Denver, CO, USA.

Peter Parham (P)

Departments of Structural Biology and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA peropa@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH